524 followers
17a) And finally, there's a new, #prespecified subgroup analysis of the Ph3 #SIENDO trial of #selinexor. Prior presentations from this work at 🧑🏫https://t.co/a3q7kpCloN 🧑🏫https://t.co/Ty7qBReD9T
Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.
Overview of attention for article published in Journal of Clinical Oncology, June 2022
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (93rd percentile)
-
High Attention Score compared to outputs of the same age and source (89th percentile)
Readers on
- mendeley
- 15 Mendeley